Medication Guide App

SNBL USA to Host Developmental Toxicology Session at the 2012 SOT Annual Meeting and ToxExpo in San Francisco, CA

Exhibitor Hosted Session scheduled on Monday, March 12, 2012 from 10:30 am – 11:30 am at the Moscone Convention Center, Room 105.

EVERETT, Wash.--(BUSINESS WIRE)--Feb 24, 2012 - SNBL USA is hosting a session entitled “Juvenile Preclinical Safety Evaluations of Biopharmaceuticals: Combining Data from Repeat Dose General and Pre/Postnatal Toxicology Studies.” This presentation session will be held during the upcoming 51st Annual Society of Toxicology Meeting taking place in San Francisco, CA in March 2012.

In regulatory-mandated NHP juvenile toxicology studies, end-points evaluated are similar to those obtained in short or long-term general toxicology studies and infants from pre/postnatal studies. Based on recent experiences, it is becoming apparent that a well deigned preclinical program requiring the NHP model presents an opportunity to incorporate evaluations that can negate the need of a stand-alone juvenile study. One of the proposed approaches is a preclinical package that includes study designs that take into consideration evaluations that can generate relevant data to cover relevant juvenile/pediatric ages. For example, this could be robust general toxicology screening studies in combination with utilization of infants data from enhanced pre/postnatal studies. Dr. Norbert Makori, SNBL USA DART Director, will present examples of data from these types of studies in the context of utilization for juvenile toxicology.

A dedicated Question & Answer session will follow the presentation where Dr. Makori will be available to answer attendees' questions. Join us in Room 105 at the Moscone Convention Center on Monday, March 12 at 10:30 am for this interactive session. We look forward to seeing you in San Francisco.

Finally, if you are attending the SOT Meeting this year, be sure to stop by the Booth #714 in the ToxExpo Hall where SNBL will be showcasing its patented procedure cage for the first time during posted exhibitor hours.

About SNBL USA, Ltd.

Headquartered in Everett, WA, SNBL USA, Ltd. offers a unique range of safety assessment services to support the drug development process. Managed and operated by a team world renowned for its wide-ranging NHP experience and expertise, we offer programs ranging from regulatory toxicology to customized study designs and disease models. Our specialized capabilities include safety assessment of biologics, reproductive toxicology, cardiovascular, respiratory and CNS pharmacology, immunotoxicology and carcinogenicity. SNBL USA's state of the art facility can house up to 4,000 NHPs. Our standing in-house colony assures a quick study start. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425-407-0121 or visit www.snblusa.com.

SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. With its multiple worldwide facilities and countless skilled and experienced scientists and technicians, SNBL Group works together in providing a full range of drug development services.

Contact: SNBL USA, Ltd.
Michelle Taylor, MA, 425-322-1950
Marketing Manager
mtaylor@snblusa.com

 

Posted: February 2012

View comments

Hide
(web3)